Shield Therapeutics has completed a fundraising

Shield Therapeutics plc has raised funds to bolster the expansion of ACCRUFeR®, the sole FDA-approved therapy for iron deficiency and to drive the business. Additionally, it positions the company for further investments.

Shield Therapeutics is a patient-focused, commercial-stage pharmaceutical company on a mission to improve the lives of people suffering from iron deficiency, enabling them to enjoy the things that make a difference in their everyday lives. Its lead medicine ACCRUFeR® (ferric maltol), is a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anemia.

Oaklins Cavendish, based in the UK, assisted Shield Therapeutics in securing its funding package.